A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) vs pmab alone in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): primary and biomarker analyses (#735)